Nanopublications

Matches in Nanopublications for { ?s ?p "[We identified RAS mutations in 16 out of 57 (28.1%) FAs, 2 out of 8 (25%) NWDTCs, 8 out of 42 (19.0%) FVPTCs, 2 out of 10 (20.0%) FTCs, 1 out of 12 (8.3%) Hurthle cell variants of FA, 3 out of 46 (6.5%) goiters, 1 out of 18 (5.6%) hyperplastic nodules, 3 out of 56 (5.4%) micro PTCs, 2 out of 115 (1.7%) PTCs, 0 out of 7 (0%) Hurthle cell variants of FTC, and 0 out of 10 (0%) HT lesions.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine."@en ?g. }

Showing items 1 to 10 of 10 with 100 items per page.

NP652952.RAc35r5Na1Fv4N35zAa2uaxG-7w-h2NFR68zWqOyLAruQ130_assertion description "[We identified RAS mutations in 16 out of 57 (28.1%) FAs, 2 out of 8 (25%) NWDTCs, 8 out of 42 (19.0%) FVPTCs, 2 out of 10 (20.0%) FTCs, 1 out of 12 (8.3%) Hurthle cell variants of FA, 3 out of 46 (6.5%) goiters, 1 out of 18 (5.6%) hyperplastic nodules, 3 out of 56 (5.4%) micro PTCs, 2 out of 115 (1.7%) PTCs, 0 out of 7 (0%) Hurthle cell variants of FTC, and 0 out of 10 (0%) HT lesions.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP652952.RAc35r5Na1Fv4N35zAa2uaxG-7w-h2NFR68zWqOyLAruQ130_provenance.
NP653226.RARh9dQkWcbOmZH_kozpDs816YagB1M_2mQBXdxPQHVZ4130_assertion description "[We identified RAS mutations in 16 out of 57 (28.1%) FAs, 2 out of 8 (25%) NWDTCs, 8 out of 42 (19.0%) FVPTCs, 2 out of 10 (20.0%) FTCs, 1 out of 12 (8.3%) Hurthle cell variants of FA, 3 out of 46 (6.5%) goiters, 1 out of 18 (5.6%) hyperplastic nodules, 3 out of 56 (5.4%) micro PTCs, 2 out of 115 (1.7%) PTCs, 0 out of 7 (0%) Hurthle cell variants of FTC, and 0 out of 10 (0%) HT lesions.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP653226.RARh9dQkWcbOmZH_kozpDs816YagB1M_2mQBXdxPQHVZ4130_provenance.
NP788478.RAW_37qEzx9I5y00L0SiZfpGMkj_bRRCMUujAh5SiE19o130_assertion description "[We identified RAS mutations in 16 out of 57 (28.1%) FAs, 2 out of 8 (25%) NWDTCs, 8 out of 42 (19.0%) FVPTCs, 2 out of 10 (20.0%) FTCs, 1 out of 12 (8.3%) Hurthle cell variants of FA, 3 out of 46 (6.5%) goiters, 1 out of 18 (5.6%) hyperplastic nodules, 3 out of 56 (5.4%) micro PTCs, 2 out of 115 (1.7%) PTCs, 0 out of 7 (0%) Hurthle cell variants of FTC, and 0 out of 10 (0%) HT lesions.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP788478.RAW_37qEzx9I5y00L0SiZfpGMkj_bRRCMUujAh5SiE19o130_provenance.
NP670654.RAAt_yukEL0hKqkwxvS5yzlA-Jbnv5uTbzV-x8jDMO88w130_assertion description "[We identified RAS mutations in 16 out of 57 (28.1%) FAs, 2 out of 8 (25%) NWDTCs, 8 out of 42 (19.0%) FVPTCs, 2 out of 10 (20.0%) FTCs, 1 out of 12 (8.3%) Hurthle cell variants of FA, 3 out of 46 (6.5%) goiters, 1 out of 18 (5.6%) hyperplastic nodules, 3 out of 56 (5.4%) micro PTCs, 2 out of 115 (1.7%) PTCs, 0 out of 7 (0%) Hurthle cell variants of FTC, and 0 out of 10 (0%) HT lesions.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP670654.RAAt_yukEL0hKqkwxvS5yzlA-Jbnv5uTbzV-x8jDMO88w130_provenance.
NP1127415.RAbt4UhJQWJ9SHjFKkBtKgdlYppX3cJ1DwzF0dzHb62LA130_assertion description "[We identified RAS mutations in 16 out of 57 (28.1%) FAs, 2 out of 8 (25%) NWDTCs, 8 out of 42 (19.0%) FVPTCs, 2 out of 10 (20.0%) FTCs, 1 out of 12 (8.3%) Hurthle cell variants of FA, 3 out of 46 (6.5%) goiters, 1 out of 18 (5.6%) hyperplastic nodules, 3 out of 56 (5.4%) micro PTCs, 2 out of 115 (1.7%) PTCs, 0 out of 7 (0%) Hurthle cell variants of FTC, and 0 out of 10 (0%) HT lesions.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1127415.RAbt4UhJQWJ9SHjFKkBtKgdlYppX3cJ1DwzF0dzHb62LA130_provenance.
NP1127411.RAv7rtD_SGOtpoyRE2GHBb6t5598gK_953_EVRwpwm21Y130_assertion description "[We identified RAS mutations in 16 out of 57 (28.1%) FAs, 2 out of 8 (25%) NWDTCs, 8 out of 42 (19.0%) FVPTCs, 2 out of 10 (20.0%) FTCs, 1 out of 12 (8.3%) Hurthle cell variants of FA, 3 out of 46 (6.5%) goiters, 1 out of 18 (5.6%) hyperplastic nodules, 3 out of 56 (5.4%) micro PTCs, 2 out of 115 (1.7%) PTCs, 0 out of 7 (0%) Hurthle cell variants of FTC, and 0 out of 10 (0%) HT lesions.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1127411.RAv7rtD_SGOtpoyRE2GHBb6t5598gK_953_EVRwpwm21Y130_provenance.
NP392478.RA-muyIKMpCVii7ZfrK_uXDF4BPupSyVyf3p5c_lUmdXY130_assertion description "[We identified RAS mutations in 16 out of 57 (28.1%) FAs, 2 out of 8 (25%) NWDTCs, 8 out of 42 (19.0%) FVPTCs, 2 out of 10 (20.0%) FTCs, 1 out of 12 (8.3%) Hurthle cell variants of FA, 3 out of 46 (6.5%) goiters, 1 out of 18 (5.6%) hyperplastic nodules, 3 out of 56 (5.4%) micro PTCs, 2 out of 115 (1.7%) PTCs, 0 out of 7 (0%) Hurthle cell variants of FTC, and 0 out of 10 (0%) HT lesions.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP392478.RA-muyIKMpCVii7ZfrK_uXDF4BPupSyVyf3p5c_lUmdXY130_provenance.
NP1127413.RAIaAFTcJu2mItdxh4o99qtq9zSRCt-w4cKZB_gM8bPGE130_assertion description "[We identified RAS mutations in 16 out of 57 (28.1%) FAs, 2 out of 8 (25%) NWDTCs, 8 out of 42 (19.0%) FVPTCs, 2 out of 10 (20.0%) FTCs, 1 out of 12 (8.3%) Hurthle cell variants of FA, 3 out of 46 (6.5%) goiters, 1 out of 18 (5.6%) hyperplastic nodules, 3 out of 56 (5.4%) micro PTCs, 2 out of 115 (1.7%) PTCs, 0 out of 7 (0%) Hurthle cell variants of FTC, and 0 out of 10 (0%) HT lesions.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1127413.RAIaAFTcJu2mItdxh4o99qtq9zSRCt-w4cKZB_gM8bPGE130_provenance.
NP1127416.RA1lQr7r9bJ9eN_5a5_DpJ9f-RZJKV-gnqwABxqF3ad54130_assertion description "[We identified RAS mutations in 16 out of 57 (28.1%) FAs, 2 out of 8 (25%) NWDTCs, 8 out of 42 (19.0%) FVPTCs, 2 out of 10 (20.0%) FTCs, 1 out of 12 (8.3%) Hurthle cell variants of FA, 3 out of 46 (6.5%) goiters, 1 out of 18 (5.6%) hyperplastic nodules, 3 out of 56 (5.4%) micro PTCs, 2 out of 115 (1.7%) PTCs, 0 out of 7 (0%) Hurthle cell variants of FTC, and 0 out of 10 (0%) HT lesions.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1127416.RA1lQr7r9bJ9eN_5a5_DpJ9f-RZJKV-gnqwABxqF3ad54130_provenance.
NP1127417.RAywon61t6iu7BrFoANZ60BYzHKzjFYF8tixPXDy4DgC8130_assertion description "[We identified RAS mutations in 16 out of 57 (28.1%) FAs, 2 out of 8 (25%) NWDTCs, 8 out of 42 (19.0%) FVPTCs, 2 out of 10 (20.0%) FTCs, 1 out of 12 (8.3%) Hurthle cell variants of FA, 3 out of 46 (6.5%) goiters, 1 out of 18 (5.6%) hyperplastic nodules, 3 out of 56 (5.4%) micro PTCs, 2 out of 115 (1.7%) PTCs, 0 out of 7 (0%) Hurthle cell variants of FTC, and 0 out of 10 (0%) HT lesions.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1127417.RAywon61t6iu7BrFoANZ60BYzHKzjFYF8tixPXDy4DgC8130_provenance.